Impact of abciximab on prognosis in diabetic patients undergoing primary percutaneous coronary intervention

Journal of Cardiovascular Medicine
Andrea PerkanGianfranco Sinagra

Abstract

The impact of diabetes in patients with acute myocardial infarction (AMI) treated with primary percutaneous coronary intervention (PCI) is unclear. The benefit of abciximab in this subset of patients remains controversial. Three hundred and twenty-seven consecutive and unselected patients with acute AMI treated with primary PCI were included in our single-center retrospective registry, 103 diabetic (31%) and 224 nondiabetic (69%). Abciximab was given at the physician's discretion. Diabetic patients were older (mean age 68.5±11 vs. 65±12 years; P=0.009), had an increased prevalence of hypertension (73 vs. 54%; P=0.001), a decreased prevalence of smoking (31 vs. 45%; P=0.02), a longer duration of symptoms before hospital admission (190 vs. 143 min; P=0.031), and a higher number of stents implanted (1.4 vs. 1.2; P=0.04). Other clinical and angiographic characteristics were comparable in the two groups. Diabetic patients had a higher incidence of the combined end-point of death and reinfarction rate at 30 days (18 vs. 10%; P=0.04) compared to nondiabetic patients. Abciximab treatment was associated with a lower in-hospital (23.8 vs. 5%; P=0.005) and 30-day (23.8 vs. 6.6%; P=0.012) mortality, and a lower incidence of death and reinf...Continue Reading

References

Oct 1, 1991·Seminars in Thrombosis and Hemostasis·D TschoepeF A Gries
Apr 1, 1990·European Journal of Clinical Investigation·D TschoepeF A Gries
Nov 1, 1989·Bratislavské lekárske listy·A Zachar
Apr 4, 1985·The New England Journal of Medicine·UNKNOWN TIMI Study Group
Oct 1, 1967·The American Journal of Cardiology·T Killip, J T Kimball
Mar 11, 1993·The New England Journal of Medicine·F ZijlstraH Suryapranata
Mar 1, 1996·Journal of the American College of Cardiology·D AronsonE J Rayfield
Jun 23, 2001·The New England Journal of Medicine·G MontalescotUNKNOWN ADMIRAL Investigators. Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long-Te
Aug 10, 2001·JAMA : the Journal of the American Medical Association·P Y LeeE D Peterson
Mar 29, 2002·The New England Journal of Medicine·Gregg W StoneUNKNOWN Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators
Oct 31, 2002·Circulation·Mandeep SinghVéronique L Roger
Sep 23, 2003·European Heart Journal·Antonio Di ChiaraUNKNOWN BLIT Investigators
Dec 10, 2003·Journal of the American College of Cardiology·David AntoniucciAntonio Colombo
Dec 10, 2003·Journal of the American College of Cardiology·Eric J TopolGilles Montalescot
Jul 14, 2004·Archives of Internal Medicine·Kristen FranklinUNKNOWN GRACE Investigators
Apr 14, 2005·JAMA : the Journal of the American Medical Association·Giuseppe De LucaEric J Topol
Jun 29, 2005·Treatments in Endocrinology·Ulrich HinkThomas Münzel
Dec 14, 2005·Pharmacology & Therapeutics·Hana FarhangkhoeeSubrata Chakrabarti
Oct 13, 2006·JAMA : the Journal of the American Medical Association·Ulf StenestrandUNKNOWN RIKS-HIA Registry
Jan 5, 2007·The New England Journal of Medicine·Ellen C Keeley, L David Hillis
Aug 21, 2007·JAMA : the Journal of the American Medical Association·Sean M DonahoeElliott M Antman
Dec 17, 2008·European Heart Journal·Frans Van de Werf

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.